NEW YORK, Oct. 19 - Invitrogen has been granted a non-exclusive sub-license from Gryphon Sciences to use its Native Chemical Ligation patent, which allow researchers to synthesize proteins using chemical, rather than biological means, Gryphon said on Friday.

The patent, numbered 6,184,344 and entitled "Synthesis of Proteins by Native Chemical Ligation," covers processes for making proteins that retain the biologic activity of the native molecule and can have specific functionality built into them, according to Gryphon. 

Financials terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.